<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242019000200410</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia de pacientes con cáncer de pulmón con metástasis cerebral en Matanzas]]></article-title>
<article-title xml:lang="en"><![CDATA[Survival of patients with lung cancer and brain metastasis in Matanzas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camacho Sosa]]></surname>
<given-names><![CDATA[Kirenia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Suárez]]></surname>
<given-names><![CDATA[Anairis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martí Martínez]]></surname>
<given-names><![CDATA[Angel Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Hernández]]></surname>
<given-names><![CDATA[Mildrey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Soto]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Clínico Quirúrgico Comandante Faustino Pérez Hernández  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Matanzas  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>41</volume>
<numero>2</numero>
<fpage>410</fpage>
<lpage>422</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242019000200410&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242019000200410&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242019000200410&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  las metástasis cerebrales cuando aparecen en el curso de un cáncer de pulmón reportan una precaria supervivencia al paciente, los tratamientos incluyen la cirugía o radiocirurgía. La radioterapia holocraneal constituye el estándar cuando los tratamientos locales no son posibles. Se han reportado respuestas del cerebro a la quimioterapia a un nivel comparable al de la enfermedad extra craneal, por lo que la terapia sistémica es una opción razonable para los pacientes sin síntomas neurológicos, o con síntomas relativamente controlados.  Objetivo:  evaluar la supervivencia de los pacientes según esquemas de tratamientos recibidos.  Materiales y métodos:  se realizó un estudio descriptivo y retrospectivo en pacientes con diagnóstico cito-histológico de cáncer de pulmón y metástasis cerebral, atendidos en la consulta externa del Centro Oncológico Provincial de Matanzas, en el período comprendido desde enero del 2013 a diciembre del 2016. Para obtener los datos de los tratamientos realizados, determinar fecha de fallecimiento o de última noticia del paciente se utilizaron las historias clínicas de los enfermos y las bases de datos del Servicio de Radioterapia del Centro.  Resultados: el 86,5% de los pacientes recibieron tratamiento con quimioterapia de primera línea, el 76% radioterapia al cerebro y el 61,5% con nimotuzumab.  Conclusiones:  la aplicación de la quimioterapia, la radioterapia holocraneal y la inmunoterapia tuvieron un valor significativo, proporcionando un aumento de la supervivencia de los pacientes estudiados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  brain metastasis report a precarious survival when they appear during the course of a lung cancer. The treatments include surgery or radiosurgery. Whole brain radiotherapy is the standard treatment when the local ones are not possible. There are reports of brain answer to chemotherapy at the level of extra brain diseases; therefore, systemic therapy is a reasonable option for the patients without neurological symptoms, or with relatively controlled symptoms.  Objective:  to assess the patients´ survival according to the schemes of the received treatments.  Materials and methods:  a retrospective descriptive study was carried out in patients with cytohistological diagnosis of lung cancer and brain metastasis, who attended the external consultation of the Provincial Oncological Center of Matanzas in the period from January 2013 to December 2016. The clinical records and databases of the Radiotherapy Service of the Center were used to obtain the data of the treatments carried out, the patients&#8217; date of dead or of the last information about them.  Results:  86.5 % of the patients received treatment with front-line chemotherapy, 76 % brain radiotherapy, and 61.5 % with Nimotuzumab.  Conclusions:  the application of chemotherapy, whole brain radiotherapy and immunotherapy achieved great improvement, increasing the survival of the studied patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer de pulmón]]></kwd>
<kwd lng="es"><![CDATA[metástasis cerebrales]]></kwd>
<kwd lng="es"><![CDATA[supervivencia]]></kwd>
<kwd lng="en"><![CDATA[lung cancer]]></kwd>
<kwd lng="en"><![CDATA[brain metastasis]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Comisión clínica de cáncer de pulmón</collab>
<source><![CDATA[Protocolo cáncer de pulmón. Diagnóstico, tratamiento y seguimiento]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Córdoba ]]></publisher-loc>
<publisher-name><![CDATA[Servicio Andaluz de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>European Society for Medical Oncology</collab>
<source><![CDATA[Cáncer de pulmón de células no pequeñas (CPCNP). Una Guía para pacientes. Información para pacientes basada en la guía clínica de la ESMO]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Francia ]]></publisher-loc>
<publisher-name><![CDATA[European Society for Medical Oncology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serizawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shuto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi- institutional prospective observational study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>387-95</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Crombet]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lage]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic Vaccination with a Therapeutic EGF-Based Cancer Vaccine: A Review of Patients Receiving Long Lasting Treatment]]></article-title>
<source><![CDATA[Current Cancer Drug Targets]]></source>
<year>2011</year>
<volume>11</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>103-10</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gastón]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>2015</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Ríosa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Concha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica]]></article-title>
<source><![CDATA[Rev Esp Patol]]></source>
<year>2015</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Herbst]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2008</year>
<volume>26</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>3351-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Grupo de Trabajo de Medicamentos Oncológicos</collab>
<source><![CDATA[Documento de Consenso sobre el Uso de Nuevos Fármacos en el Tratamiento del Cáncer de Pulmón]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Murcia ]]></publisher-loc>
<publisher-name><![CDATA[Consejería de Sanidad y Política Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matus-Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Motola]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importancia de la detección de metástasis cerebrales en pacientes con carcinomas en estadios avanzados]]></article-title>
<source><![CDATA[Rev Invest Med Sur Mex]]></source>
<year>2012</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>222-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>American Society of Clinical Oncology</collab>
<article-title xml:lang=""><![CDATA[Cáncer de pulmón-células no pequeñas: Opciones de tratamiento]]></article-title>
<source><![CDATA[Cancer. Net Editorial Board]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Comisión clínica de cáncer de pulmón</collab>
<source><![CDATA[Protocolo cáncer de pulmón. Diagnóstico, tratamiento y seguimiento]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Córdoba ]]></publisher-loc>
<publisher-name><![CDATA[Servicio Andaluz de Salud. Consejería de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlos Buzaid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cotait]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha Lima]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Oncología Clínica de Brasil 2012]]></source>
<year>2013</year>
<edition>6</edition>
<publisher-loc><![CDATA[Brasil ]]></publisher-loc>
<publisher-name><![CDATA[Centro Avanzado de Oncología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gondi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pugh]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Tome]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>3810-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>UGC de Cirugía Torácica y Trasplante Pulmonar</collab>
<collab>UGC de Oncología Médica</collab>
<collab>UGC de Oncología Radioterápica</collab>
<source><![CDATA[Guía de tratamiento del carcinoma del pulmón]]></source>
<year>2015</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Junta de Andalucía]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serizawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shuto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi- institutional prospective observational study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>387-95</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barajas]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastasis in Adult Brain Tumors]]></article-title>
<source><![CDATA[Neuroimag Clin N Am]]></source>
<year>2016</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>601-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gondi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pugh]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Tome]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preservation of memorywith conformal avoidance of the hippocampal neural stemcell compartment during whole-brain radiotherapy for brainmetastases (RTOG 0933): a phase II multi-institutional trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>3810-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jancalek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pospisil]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why and how to spare the hippocampus during brain radiotherapy: the developing role ofhippocampal avoidance in cranial radiotherapy]]></article-title>
<source><![CDATA[Radiat Oncol]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>139</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moraes]]></surname>
<given-names><![CDATA[FY]]></given-names>
</name>
<name>
<surname><![CDATA[Taunk]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Marta]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brain metastases]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2016</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>244-51</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Asher]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ballman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy(WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3brain metastases]]></article-title>
<source><![CDATA[J Clin Onco l]]></source>
<year>2015</year>
<volume>33</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crombet]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer]]></article-title>
<source><![CDATA[J Immunother]]></source>
<year>2003</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>139-48</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gastón]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>2015</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crombet-Ramos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2002</year>
<volume>101</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>567-75</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brastianos]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Santagata]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets]]></article-title>
<source><![CDATA[Cancer Discov]]></source>
<year>2015</year>
<volume>5</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1164-77</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eastman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New Dartmouth Atlas Report on Medicare Patients with Advanced Cancer: More Use of Hospice, but Aggressive Therapy at End of Life Continues]]></article-title>
<source><![CDATA[Oncology Times]]></source>
<year>2013</year>
<volume>35</volume>
<numero>19</numero>
<issue>19</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
